EXEL终于爆了# Stock
j*u
1 楼
可惜，没耐心等到今天。
Exelixis (EXEL_) shares are soaring 22.7% to $4.08 on Monday after it
announced positive top of the line results for its phase 3 study in which
the company's advanced melanoma drug treatment, cobimetinib, met its primary
endpoint of a statistically significant increase in progression-free
survival compared to patients who took another treatment, Zelboraf, alone.
Exelixis (EXEL_) shares are soaring 22.7% to $4.08 on Monday after it
announced positive top of the line results for its phase 3 study in which
the company's advanced melanoma drug treatment, cobimetinib, met its primary
endpoint of a statistically significant increase in progression-free
survival compared to patients who took another treatment, Zelboraf, alone.
